[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341096-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341096-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lack-of-shared-neoantigens-in-prevalent-mutations-in-cancer-research-findings-and-immunological-implications","Lack of shared neoantigens in prevalent mutations in cancer - Research findings and immunological implications","","Tumors arise through genetic instability, where DNA damage checkpoint, DNA repair machinery, and mitotic checkpoint defects allow mutations to accumulate. Many driver mutations are positively selected during cancer evolution and, if they generate mutated neoantigens, could enable targeted cancer vaccines and/or adoptive cell therapies. Analysis shows that highly prevalent human cancer mutations do not express mutated neoantigens, suggesting early immune negative selection. As a result, shared mutated neoantigen vaccines appear unlikely, highlighting a key immune role in tumor antigen presentation and antitumor immunological strategy development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lack-of-shared-neoantigens-in-prevalent-mutations-in-cancer-research-findings-and-immunological-implications/341096/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lack-of-shared-neoantigens-in-prevalent-mutations-in-cancer-research-findings-and-immunological-implications/341096.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do tumors accumulate mutations?","Question",{"text":63,"@type":64},"Tumors show genetic instability because defects in DNA damage checkpoint, DNA repair, or mitotic checkpoint allow mutations to accumulate over time.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the analysis find about prevalent cancer mutations and neoantigen expression?",{"text":68,"@type":64},"The most prevalent mutations in human cancers do not express mutated neoantigens, contrary to what would be expected if shared driver mutations produced actionable neoantigens.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the immune system shape tumor antigen presentation according to the paper?",{"text":72,"@type":64},"The results propose early immune-system selection: cells producing highly antigenic non-self-mutated neoantigens are eliminated, preventing outgrowth and limiting shared mutated neoantigen vaccine targets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341096,1790790313,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Ragone etal.  \nJournal of Translational Medicine (2024) 22:344 [https://doi.org/10.1186/s12967-024-05110-0](https://doi.org/10.1186/s12967-024-05110-0)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nLack of shared neoantigens in prevalent mutations in cancer  \nConcetta Ragone 1, Beatrice Cavalluzzo1, Angela Mauriello 1, Maria Tagliamonte1* and Luigi Buonaguro 1*  \nAbstract  \nTumors are mostly characterized by genetic instability, as result of mutations in surveillance mechanisms, such as DNA damage checkpoint, DNA repair machinery and mitotic checkpoint. Defect in one or more of these mechanisms causes additive accumulation of mutations. Some of these mutations are drivers of transformation and are positively selected during the evolution of the cancer, giving a growth advantage on the cancer cells. If such mutations would result in mutated neoantigens, these could be actionable targets for cancer vaccines and/or adoptive cell therapies. However, the results of the present analysis show, for the first time, that the most prevalent mutations identified in human cancers do not express mutated neoantigens. The hypothesis is that this is the result of the selection operated by the immune system in the very early stages of tumor development. At that stage, the tumor cells characterized by mutations giving rise to highly antigenic non-self-mutated neoantigens would be efficiently targeted and eliminated. Consequently, the outgrowing tumor cells cannot be controlled by the immune system, with an ultimate growth advantage to form large tumors embedded in an immunosuppressive tumor microenvironment (TME) . The outcome of such a negative selection operated by the immune system is that the development of off-the-shelf vaccines, based on shared mutated neoantigens, does not seem to be at hand. This finding represents the first demonstration of the key role of the immune system on shaping the tumor antigen presentation and the implication in the development of antitumor immunological strategies.  \nKeywords Mutations, Neoantigens, Tumor-associated antigens, Tumor-specific antigens, Cancer vaccines, Molecular mimicry, T cell immunity  \nIntroduction  \nSomatic mutations occur in the genomes of all normal and neoplastic dividing cells. They are the result of errors occurring during DNA replication as well as exposure to exogenous or endogenous mutagens. However, if most of these mutations are repaired by cellular mechanisms, a minority remains fixed in the cell genome. Most of such  \n*Correspondence:  \nMaria Tagliamonte [m.tagliamonte@istitutotumori. na.it](m.tagliamonte@istitutotumori. na.it)[ ](m.tagliamonte@istitutotumori. na.it)Luigi Buonaguro  \nl.buonaguro@istitutotumori. na.it  \n1 Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS- “Fondazione Pascale”, Via Mariano Semmola, 52, 80131 Naples, Italy  \nfixed mutations are biologically neutral and already present in the progenitor cell, before the transformation into the final clonal cancer cell (“passenger” mutations). The remaining ones are “driver” mutations that confer growth advantage on the cell, increasing survival or proliferation, and are selected. The accumulation of the driver mutations over the lifetime of an individual will induce cell transformation and cancer development [1–3]. The number of mutations required to drive a cancer significantly varies across tumor types [4]. Studies have shown that carcinogenesis may be driven by a small number of driver mutations. In particular, one driver mutation per patient is sufficient in sarcomas, thyroid, and testicular cancers; and about four driver mutations per patient are needed in bladder, endometrial, and colorectal cancers [1, 2, 5]. The different mutations in cancer cells show different  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any mediu","cbCaicEFrXGawAPG","https://ap.wps.com/l/cbCaicEFrXGawAPG","pdf",3314881,17,"English","# Abstract\n# Introduction\n## Driver and passenger mutations\n## Neoantigens and cancer vaccines","[{\"question\":\"Why do tumors accumulate mutations?\",\"answer\":\"Tumors show genetic instability because defects in DNA damage checkpoint, DNA repair, or mitotic checkpoint allow mutations to accumulate over time.\"},{\"question\":\"What did the analysis find about prevalent cancer mutations and neoantigen expression?\",\"answer\":\"The most prevalent mutations in human cancers do not express mutated neoantigens, contrary to what would be expected if shared driver mutations produced actionable neoantigens.\"},{\"question\":\"How does the immune system shape tumor antigen presentation according to the paper?\",\"answer\":\"The results propose early immune-system selection: cells producing highly antigenic non-self-mutated neoantigens are eliminated, preventing outgrowth and limiting shared mutated neoantigen vaccine targets.\"}]","Lack of shared neoantigens in prevalent mutations in cancer - Research findings and immunological implications | PDF",1790040300,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5ec4501bf759dd393fb01407dad8da2.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4f4476721ce68436d0c09c5eb8df954.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80b1240096e680aae1dbe4f10ee9afdf.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8483933baa53ca23b148b1524eff5c8.webp",980,1301]